BAIT VACCINE AGAINST LYME BORRELIOSIS

Information

  • Research Project
  • 7218534
  • ApplicationId
    7218534
  • Core Project Number
    R43AI072810
  • Full Project Number
    1R43AI072810-01
  • Serial Number
    72810
  • FOA Number
    PA-06-34
  • Sub Project Id
  • Project Start Date
    9/15/2007 - 18 years ago
  • Project End Date
    8/31/2009 - 16 years ago
  • Program Officer Name
    BREEN, JOSEPH J.
  • Budget Start Date
    9/15/2007 - 18 years ago
  • Budget End Date
    8/31/2008 - 17 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/7/2007 - 18 years ago
Organizations

BAIT VACCINE AGAINST LYME BORRELIOSIS

[unreadable] DESCRIPTION (provided by applicant): Lyme disease is caused by the spirochete Borrelia burgdorferi. This zoonosis is the most prevalent vector borne infectious disease in the United States and Europe and it continues to grow geographically. The enzootic cycle of this pathogen requires that Ixodes spp. acquire B. burgdorferi from infected wildlife reservoirs and transmit it to other uninfected wildlife. At present, there are no effective measures to control B. burgdorferi; there is no human vaccine available, and, existing vector control measures are generally not acceptable to the public. However, if B. burgdorferi could be eliminated from its reservoir hosts and from the ticks that feed on them, the enzootic cycle would be broken, and the incidence of Lyme disease would decrease. To accomplish this, we developed an OspA-based bait vaccine and demonstrated that, in the Lyme disease mouse model, ad libidum feeding induced systemic anti-OspA IgG and protected all vaccinated mice from B. burgdorferi infection after tick challenge. In addition, these anti-OspA antibodies cleared B. burgdorferi from the tick vector. Thus, this bait vaccine is a good candidate to break the enzootic cycle of this pathogen. The major goal of this Phase I SBIR proposal is to test a bait vaccine by ad libidum feeding of the natural host reservoir of this spirochete, the white-footed mouse, Peromyscus leucopus. After treatment, we will assess vaccine efficacy by analyzing B. burgdorferi infection prevalence of the host and of the tick vector. We will carry out experiments both in the laboratory and in the wild. The fieldwork component of this project will be performed at the Institute for Ecosystem Studies (IES) in Millbrook, NY. In a subsequent Phase II SBIR proposal, we would expand our field studies to span the two-year life cycle of the tick vector and assess different vehicles for bait delivery. Lyme disease is the most prevalent vector borne infectious disease in the United States and Europe, and its geographical range is expanding. One way to reduce the incidence of Lyme disease is to eliminate B. burgdorferi from its reservoir and/or from the ticks that feed on them, breaking the mouse-tick cycle. The goal of this Phase I SBIR proposal is to test a bait vaccine against B. burgdorferi via ad libidum feeding of the major host reservoir of this spirochete, the white-footed mouse. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    299996
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:299996\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOPEPTIDES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    EAST SETAUKET
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    117333728
  • Organization District
    UNITED STATES